EUVIMEDEUVIMED entdecken
Kommentar

Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection

Jakob A Østergaard, Mark E Cooper

Kidney International · 2026-07 · 110 (1) · 33-34

DOI: 10.1016/j.kint.2026.04.006 ↗

Kurz gefasst

Kommentar in der Zeitschrift Kidney International, 2026-07. Verfasst von Jakob A Østergaard und 1 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University Hospi…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-1, Kidney. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease remains a major clinical challenge despite advances in renoprotective therapies. In this issue of Kidney International, Qi et al. report that selective modulation of the vascular endothelial growth factor (VEGF) system differentially affects diabetic kidney disease progression across multiple advanced diabetic models. Whereas VEGF-A or VEGF receptor 2 inhibition exacerbated albuminuria, targeted VEGF receptor 1 blockade consistently conferred renoprotection, including in established disease. These findings clarify prior conflicting data and identify VEGF receptor 1 inhibition as a therapeutic strategy for diabetic kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1KidneyAnimalsHumansVascular Endothelial Growth Factor Receptor-2AlbuminuriaDisease Progression

Substanzen

Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2

Autor:innen und Institutionen

  • Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia. Electronic address: mark.cooper@monash.edu.

Zitieren

APA

Østergaard, J. A., & Cooper, M. E. (2026). Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection. Kidney International, 110(1), 33-34. https://doi.org/10.1016/j.kint.2026.04.006

Vancouver

Østergaard JA, Cooper ME. Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection. Kidney International. 2026;110(1):33-34. doi:10.1016/j.kint.2026.04.006

BibTeX
@article{stergaard2026,
  author = {Østergaard, Jakob A and Cooper, Mark E},
  title = {Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection},
  journal = {Kidney International},
  year = {2026},
  volume = {110},
  number = {1},
  pages = {33--34},
  doi = {10.1016/j.kint.2026.04.006}
}
Kostenlos starten →